Predictors of immune recovery and the association with late mortality while on antiretroviral treatment in Cambodia (Q39550582)

13 September 2017

title

Predictors of immune recovery and the association with late mortality while on antiretroviral treatment in Cambodia (English)

1 reference

13 September 2017

main subject

anti-retroviral agent

0 references

0 references

1

Johan van Griensven

1 reference

13 September 2017

Sopheak Thai

2

1 reference

13 September 2017

publication date

2 October 2011

1 reference

Transactions of the Royal Society of Tropical Medicine and Hygiene

13 September 2017

published in

1 reference

13 September 2017

volume

105

1 reference

13 September 2017

issue

12

1 reference

13 September 2017

page(s)

694-703

1 reference

Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Mortality associated with discordant responses to antiretroviral therapy in resource-constrained settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Very early mortality in patients starting antiretroviral treatment at primary health centres in rural Malawi

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Five-year experience with scaling-up access to antiretroviral treatment in an HIV care programme in Cambodia

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Immunologic and virologic predictors of AIDS-related non-hodgkin lymphoma in the highly active antiretroviral therapy era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

An algorithm to optimize viral load testing in HIV-positive patients with suspected first-line antiretroviral therapy failure in Cambodia

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Effect of early versus deferred antiretroviral therapy for HIV on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Initiation of antiretroviral therapy among pregnant women in resource-limited countries: CD4+ cell count response and program retention

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Gender differences in antiretroviral treatment outcomes of HIV patients in rural Uganda

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Is there a gender gap in the HIV response? Evaluating national HIV responses from the United Nations General Assembly Special Session on HIV/AIDS country reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Virologic and immunologic response to HAART, by age and regimen class

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Human immunodeficiency virus in an aging population, a complication of success

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Discordant immunological and virological responses to antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Class-sparing regimens for initial treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Determinants of Mortality and Nondeath Losses from an Antiretroviral Treatment Service in South Africa: Implications for Program Evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Modeling changes in CD4-positive T-lymphocyte counts after the start of highly active antiretroviral therapy and the relation with risk of opportunistic infections: the Aquitaine Cohort, 1996-1997

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

Virologic, Immunologic, and Clinical Response to Highly Active Antiretroviral Therapy: the Gender Issue Revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

HIV and aging: time for a new paradigm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2011.08.007

10.1016/J.TRSTMH.2011.08.007

7 January 2021

Identifiers

DOI

1 reference

13 September 2017

1 reference